Cargando…

RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients

BACKGROUND: Adjuvant chemotherapy is a major adjuvant treatment modality for hormonal receptor (HR)-positive and HER2-negative early breast cancer, but only 2%-20% of patients derive practical benefits. How to balance its potential benefits and risks becomes a challenging clinical problem. The purpo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Haibo, Ma, Li, Zhang, Yanan, Wang, Ouchen, Wei, Zhimin, Xie, Xiaohong, Zha, Xiaoming, Zeng, Jian, Lv, Qing, Ren, Yu, Wang, Huimin, Du, Furong, Cao, Shangzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769189/ https://www.ncbi.nlm.nih.gov/pubmed/36568204 http://dx.doi.org/10.3389/fonc.2022.896431

Ejemplares similares

The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients
por: Zhang, Shuo, et al.
Publicado: (2021)

Prognostic Comparison between Oncotype DX(®) and a 23-Gene Classifier, RecurIndex(®), on the Taiwan Breast Cancer Population
por: Chang, Chuan-Hsun, et al.
Publicado: (2022)

Cost-Effectiveness Analysis from a Societal Perspective of Recurrence Index for Distant Recurrence (RecurIndex) in Women with Hormone Receptor-Positive and HER2-Negative Early-Stage Breast Cancer
por: Pennarun, Nicolas, et al.
Publicado: (2022)

Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
por: Alexandre, Marie, et al.
Publicado: (2019)

Are We Prepared for the CDK4/6 Revolution With HR+/HER2− Breast Cancers?: The Importance of Patient Adherence to Adjuvant Therapies
por: Azoz, Seyla, et al.
Publicado: (2023)

The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
por: Wang, Yukun, et al.
Publicado: (2021)

21-Gene Recurrence Assay Associated With Favorable Metabolic Profiles in HR-Positive, HER2-Negative Early-Stage Breast Cancer Patients
por: Zhu, Yifei, et al.
Publicado: (2021)

Recurring Themes
por: Imperiale, Michael J.
Publicado: (2020)

Recurring Grippe
por: Love, I. N.
Publicado: (1894)

Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review
por: Wang, Wei, et al.
Publicado: (2023)

Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2023)

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
por: Johnston, Stephen R. D., et al.
Publicado: (2020)

Adjuvant chemotherapy guidance for pT1–3N0–1 breast cancer patients with HR(+), HER2(−) subtype: a cohort study based on the SEER database
por: Wen, Nan, et al.
Publicado: (2021)

Recurring Cervical Chondroma
Publicado: (1928)

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
por: Nardin, Simone, et al.
Publicado: (2023)

Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials
por: Gao, Hong-Fei, et al.
Publicado: (2021)

Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2023)

Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2(+)HR(+) breast cancer
por: Bu, Jiawen, et al.
Publicado: (2023)

Controversies and Opportunities in the Clinical Daily Use of the 21-Gene Assay for Prognostication and Prediction of Chemotherapy Benefit in HR+/HER2- Early Breast Cancer
por: Jacobs, Flavia, et al.
Publicado: (2022)

Effect of HER2 expression status on the prognosis of patients with HR(+)/HER2(‑) advanced breast cancer undergoing advanced first‑line endocrine therapy
por: Wang, Kan, et al.
Publicado: (2023)

Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer
por: Gogate, Anagha, et al.
Publicado: (2023)

ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)
por: Ferrando, Lorenzo, et al.
Publicado: (2023)

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019)

Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer
por: Stellato, Daniel, et al.
Publicado: (2021)

American Society of Clinical Oncology 2021 Podcast: HR+, HER2− Breast Cancer
por: Cheung, Kwok-Leung
Publicado: (2021)

Recurring Jaundice in Successive Pregnancies
Publicado: (1914)

Recurring Facial Erythema in an Infant
por: Hassan, Sam, et al.
Publicado: (2016)

Recurring Torsion of the Spermatic Cord
por: Dowden, J. W.
Publicado: (1905)

Recurring Luxation of the Lower Jaw
Publicado: (1891)

Pilomatrixoma Recurring as Giant Form
por: Tavares, Ana Teresa, et al.
Publicado: (2022)

Pediatric ependymomas: destined to recur?
por: Ritzmann, Timothy A, et al.
Publicado: (2021)

Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis
por: Salvo, Elizabeth M., et al.
Publicado: (2021)

Benefits of Adjuvant Chemotherapy Differ by Menopausal Status in Women with HR+/HER2- Early Breast Cancer, 1-3 Positive Nodes, and a Low Recurrence Score
por: Jacobson, Anne
Publicado: (2022)

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
por: Ma, Jing, et al.
Publicado: (2022)

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
por: Shikata, Shohei, et al.
Publicado: (2023)

Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry
por: Martín, Miguel, et al.
Publicado: (2023)

Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR
por: Dey, Nandini, et al.
Publicado: (2021)

Management of HR+/HER2+ lobular breast cancer and trends do not mirror better outcomes
por: Yaghi, Marita, et al.
Publicado: (2022)

Robust Guidelines for the Management of HR+ Her2− EBC: Crucial Value of CanAssist Breast
por: Vaid, Ashok, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3i5aiafgpmirpuc6i4dqca8bj2